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Aims: To assess health-related quality of life (HRQoL) in people with type 2 diabetes (T2D) par-
ticipating in the LEADER cardiovascular outcomes trial using the five-dimension European Qual-
ity of Life questionnaire (EQ-5D).
Materials and methods: The EQ-5D was administered every 12 months in a subset of patients
from Canada, Denmark, Germany, Ireland, Italy, Netherlands, Spain, Sweden, the United King-
dom and the United States. We compared changes in utility index scores and visual analogue
scale (VAS) scores from baseline to 36 months in participants treated with liraglutide and pla-
cebo. We also assessed which complications had the greatest impact on quality of life.
Results: At 36 months, less deterioration in EQ-5D utility index score was seen in the liraglutide
group (−0.058) than in the placebo group (−0.082; estimated treatment difference [ETD] 0.023,
95% confidence interval [CI] 0.004;0.043; P = 0.020). A smaller decrease in EQ-5D VAS score
was also demonstrated in the liraglutide group (−3.51) vs. the placebo group (−5.45; ETD 1.94,
95% CI 0.32;3.57; P = 0.019). The benefits of liraglutide treatment compared with placebo were
driven primarily by shifts in the domains of mobility and self-care. The most influential events
contributing to poorer HRQoL were stroke, heart failure, malignant neoplasm and confirmed
hypoglycaemia.
Conclusions: Liraglutide demonstrated a modest but significant benefit in patient-reported
health status using the EQ-5D, compared with placebo. This benefit may be of clinical relevance
and requires further study.
KEYWORDS
EQ-5D, health-related quality of life, LEADER, liraglutide, patient-reported outcomes, type
2 diabetes
1 | INTRODUCTION
Health-related quality of life (HRQoL) is an important component in
the evaluation of disease burden, such as that in diabetes, and can
be measured as a patient-reported outcome. According to the Ameri-
can Diabetes Association guidelines, improved quality of life is a key
goal of diabetes management and should be monitored as part of
routine care.1 The full extent of a treatment's overall efficacy may be
better gauged by considering patient-reported outcomes such as
HRQoL.2
Data relating to HRQoL are increasingly being collected during
clinical trials in patients with type 2 diabetes (T2D).2–4 However, of
the recent large outcome trials in diabetes, only SAVOR-TIMI 53 has
so far published HRQoL results,5 and reported no significant differ-
ence between saxagliptin and placebo in mean levels of HRQoL using
the five-dimension European Quality of Life questionnaire (EQ-5D),
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which was administered to all patients at baseline, 12 and 24 months
and at study completion, and at semi-annual visits to patients who
had experienced a non-fatal myocardial infarction (MI) or ischaemic
stroke since their previous visit.
The Liraglutide Effect and Action in Diabetes: Evaluation of car-
diovascular outcome Results (LEADER) trial was a randomized,
double-blind, placebo-controlled trial for up to 5 years in patients with
T2D at high risk of cardiovascular (CV) disease. The study showed a
reduced risk for CV outcomes (hazard ratio [HR] 0.87, 95% confidence
interval [CI] 0.78-0.97), all-cause mortality (HR 0.85, 95% CI
0.74-0.97), hypoglycaemia and microvascular outcomes in patients
treated with liraglutide vs. those treated with placebo.6,7 To gain some
insight into the HRQoL of the LEADER trial participants, assessments
of the three-level version of the EQ-5D (EQ-5D-3 L) were collected
from a subset of patients from 10 countries annually. The EQ-5D util-
ity index score and visual analogue scale (VAS) scores are reported
here as a pre-specified secondary analysis, with post hoc analyses of
further HRQoL outcomes.
2 | MATERIALS AND METHODS
2.1 | Study design and oversight
The trial protocol of LEADER has been described elsewhere.8 LEADER
was a double-blind, placebo-controlled trial with a follow-up of 3.5 to
5 years. Patients with T2D and high risk of CV disease were randomly
assigned (1:1 ratio) to subcutaneous liraglutide (n = 4668) or matching
subcutaneous placebo (n = 4672), both in addition to standard of
care. The trial was approved by institutional review boards, and all
patients provided written informed consent. The disposition of trial
participants has been published.6 Assessing patient-reported out-
comes measured by EQ-5D-3 L (hereafter referred to as EQ-5D) was
a pre-specified secondary outcome of the LEADER trial, and EQ-5D
scores were assessed in all patients from Canada, Denmark, Germany,
Ireland, Italy, Netherlands, Spain, Sweden, the United Kingdom and
the United States because validated EQ-5D questionnaires were avail-
able in the languages of these countries. The 3014 patients participat-
ing in the EQ-5D assessments represent 32.3% of the total LEADER
population. These patients completed a paper version of the EQ-5D
questionnaire while attending clinic visits at randomization and every
12 months until trial end. These data were transcribed into the elec-
tronic case report form by the site staff.
2.2 | EQ-5D-3L
The EQ-5D is a preferred instrument for measuring health utilities by clini-
cal guidance bodies, is based on patient preferences and produces utility
scores that can be used for cost-effectiveness studies across diseases.9 It
is one of the most widely used generic preference-based measures of
HRQoL10 and consists of two parts: a descriptive system and a VAS.
The descriptive system covers five dimensions of self-reported
health: mobility; self-care; usual activities; pain/discomfort; and anxi-
ety/depression. Each dimension of the EQ-5D-3L has three response
category levels (no problems, some problems and extreme problems),
allowing a total of 243 possible health states. Each of these health
states has an accompanying utility index score or preference-based
weight, sets of which are available for different countries. In the pre-
sent study, the UK value set was used, derived from a valuation exer-
cise conducted in a large population sample.11 The resulting
valuations or utilities range from −0.543 to 1, where negative values
are considered worse than death, a value of 0 represents death, and a
value of 1 indicates perfect health.11
The EQ-5D also has a VAS, which consists of a 100-point scale
on which patients indicate their health score; the best state carries a
score of 100 and the worst state a score of 0.12
It is also possible to analyse EQ-5D responses in terms of answers
to each question; for example, proportions selecting each level of each
question, or movements when the EQ-5D is used sequentially. In this
case, nine shifts are possible, listed in order of severity, defined as:
extreme problems to no problems; some problems to no problems; no
problems and no change; extreme problems to some problems; some
problems and no change; no problems to some problems; extreme
problems and no change; some problems to extreme problems; and
no problems to extreme problems.
2.3 | Statistical analyses
Changes from baseline to 36 months in quality-of-life (EQ-5D) utility
index score and VAS were analysed using a linear mixed model for
repeated measurements. In case of death, both the utility index score
and VAS value were set to 0 at the first planned visit after death. Pre-
specified comparisons to estimate the treatment differences (liraglutide
vs. placebo) were performed at 36 months; with a trial duration of
3.5-5 years, this was the final visit at which EQ-5D assessments were
available for the majority of the patients included. To assess the influence
of imputing values for death (0 for both utility index score and VAS), the
analyses were also repeated with the imputed values for death removed.
The distribution of all possible ranked categorical shifts in individ-
ual domain states between baseline and 36 months was compared
between treatments using a Kruskal-Wallis test. The categorical shifts
are presented as “worsening”, “no change” and “improvement”. Cate-
gorical shifts in overall utility index score between baseline and
36 months were also assessed. A score of 1 equated to perfect health
and a score of <1 equated to problems.
Changes in EQ-5D utility index scores associated with complica-
tions during follow-up, that is, stroke, malignant neoplasm, severe hypo-
glycaemia (requiring assistance from another person to treat),
confirmed hypoglycaemia (severe hypoglycaemia and/or plasma glu-
cose <3.1 mmol/L [56 mg/dL]), MI, heart failure (HF), foot ulcer, reti-
nopathy and nephropathy, were explored using a linear mixed model.
Insulin initiation, weight reduction of 5% and a glycated haemoglobin
(HbA1c) <58 mmol/mol were also included. These factors are time-
varying and were assigned a status of “no” at all time points for EQ-5D
measurements before the given event, and a status of “yes” at time
points after a given event. Other factors included treatment, sex, region,
CV risk at baseline and interaction between visit and age group.
Because of the exploratory nature of these analyses, no adjust-
ments for multiple statistical comparisons were made to the P values,
as defined in the prespecified statistical analysis plan for the trial.
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3 | RESULTS
3.1 | Baseline characteristics and primary outcome
of included patients
In LEADER, 9340 patients were randomized (4668 to liraglutide and
4672 to placebo), with a median follow-up of 3.8 years. At baseline,
3014 patients were included in this sub-study, and 2460 patients
completed the EQ-5D at 36 months. Baseline characteristics of the
3014 patients included with EQ-5D measurements were well bal-
anced between the randomized treatment groups (Table 1). Patients
were on average older than the full trial cohort (65.6 vs. 64.3 years,
respectively), had a higher body mass index (BMI; 33.2 vs. 32.5 kg/m2,
respectively) and a similar mean diabetes duration (12.6 vs. 12.8 years,
respectively). The proportion of insulin-naive patients at baseline was
42.0%, vs. 55.4% in the total trial cohort. Baseline EQ-5D index scores
were similar between treatment groups (0.79 and 0.78 for liraglutide
and placebo groups, respectively), as were baseline VAS scores (74.7
vs. 74.3 for liraglutide and placebo groups, respectively).
Of the 3014 patients included from the 10 countries in this sub-
study, 187 treated with liraglutide (12.4%) and 221 treated with pla-
cebo (14.7%) experienced a major adverse CV event. This proportion
of patients with a primary endpoint in the liraglutide and placebo
groups is consistent with that reported in the overall trial population
(13.0% and 14.9% with liraglutide and placebo, respectively).6
3.2 | Overall change in EQ-5D utility index and VAS
scores
EQ-5D scores declined in both treatment groups during the trial. By
36 months, less deterioration in EQ-5D utility index score was seen in
the liraglutide group (−0.058) than in the placebo group (−0.082; esti-
mated treatment difference [ETD] 0.023, 95% CI 0.004-0.043;
P = 0.020 [Figure 1A]). A smaller decrease in EQ-5D VAS score was
also demonstrated in the liraglutide (−3.51) vs. placebo group (−5.45;
ETD 1.94, 95% CI 0.32-3.57; P = 0.019 [Figure 1B]).
Fewer patients with EQ-5D measurements died in the liraglutide
group (n = 99) than in the placebo group (n = 131), and the treatment
difference seen in utility score and VAS could be attributable to the
difference in the number of patients who died. However, when not
including the values of 0 at the first planned visit after death, esti-
mates for the EQ-5D utility index at 36 months still declined less in
the liraglutide (−0.027) compared with the placebo group (−0.046;
ETD 0.018, 95% CI 0.001-0.035; P = 0.034). A smaller decrease in
EQ-5D VAS score was also seen in the liraglutide (−0.146) vs. placebo
group (−1.449) with imputed values of death removed (ETD 1.302,
95% CI 0.101;2.504; P = 0.034).
3.3 | Categorical shifts in EQ-5D at 36 months
The benefits of liraglutide treatment compared with placebo, seen in
utility score, were driven primarily by shifts in the domains of mobility
(P = 0.036) and self-care (P = 0.041). A greater proportion of patients
reported an improvement in mobility in the liraglutide (9.4%) com-
pared with the placebo group (6.6%). Fewer liraglutide-treated
patients reported worsening in self-care in the trial (4.6%),
vs. placebo-treated (7.4%). To a lesser degree, pain and discomfort
also contributed to the shifts in utility score, whereas there were no
treatment differences in the other domains (usual activities and anxi-
ety/depression; Table 2). Analyses of categorical changes according to
separation of patients into binary categories of perfect health (utility
index score = 1; no problems) and any problems (utility index score <
1; problems) did not show any significant treatment differences
(Table 3), indicating that the differences were mainly a consequence
of quantitative changes in the patients with some level of “problems”
at both baseline and 36 months.
3.4 | Change in utility index score and VAS for key
factors and events
The most influential events contributing to differences in HRQoL
were stroke, HF, malignant neoplasm and confirmed hypoglycaemia
(Figure 2).
Reductions in HRQoL were seen in patients with either stroke
(P = 0.001) or HF (P < 0.0001), with a greater impact of stroke than
HF on HRQoL, as evidenced by the larger impact on the VAS score
(P < 0.0001) than HF (P = 0.264; Figure 2).
Malignant neoplasm also had a small impact on HRQoL, seen in
both the total index score (P = 0.0029) and VAS (P = 0.0003;
Figure 2).
Confirmed hypoglycaemia had a small impact on HRQoL, as illus-
trated by the total index score (P < 0.0001) but not the VAS
(P = 0.978; Figure 2). Severe hypoglycaemia also indicated an associa-
tion with HRQoL reduction, although not statistically significant, pos-
sibly because of the low numbers of patients with severe
hypoglycaemic events (change in total index score: −0.029;
VAS: −1.416).
Achieving HbA1c <58 mmol/mol had a small positive impact on
HRQoL, and initiation of insulin had a small negative impact; the
TABLE 1 Baseline characteristics of patients with five-dimension
European quality of life questionnaire measurements
Liraglutide
N = 1506
Placebo
N = 1508
Age, years 65.3 (7.3) 65.9 (7.0)
BMIa, kg/m2 33.4 (6.3) 33.1 (5.9)
Weight, kg 97.2 (20.5) 95.7 (19.1)
HbA1c, mmol/mol 68 (15) 68 (14)
Duration of diabetesa, years 12.5 (7.7) 12.7 (8.2)
Insulin-naive, n (%) 620 (41.2) 645 (42.8)
Years of observationb, years 3.9 (0.6) 3.9 (0.7)
EQ-5D index score 0.79 (0.24) 0.78 (0.24)
EQ-5D VAS score 74.7 (17.2) 74.3 (17.9)
Abbreviations: BMI, body mass index; EQ-5D, five-dimension European
Quality of Life questionnaire; HbA1c, glycated haemoglobin; N, number of
patients with EQ-5D measurements; VAS, visual analogue scale.
Full analysis set. Data are mean (standard deviation, SD) unless otherwise
stated.
a BMI data only available for 1505 and 1506 patients in the liraglutide and
placebo treatment groups, respectively; duration of diabetes data only
available for 1505 and 1503 patients, respectively.
b Including follow-up years.
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former demonstrated in the total index score (P = 0.020) and not the
VAS (P = 0.599), and vice versa for initiation of insulin (VAS:
P = 0.023; total index score: P = 0.066 [Figure 2]).
Foot ulcers might impact HRQoL but this complication had
no statistically significant influence on the total utility index score
or VAS, potentially because of the low event numbers (total index
score: −0.023; VAS: −1.881). Weight loss of 5% also demon-
strated no impact on HRQoL (total index score: 0.008; VAS:
0.235); other events that appeared not to affect either the utility
index score or VAS were non-fatal MI, retinopathy and nephropa-
thy (Figure 2).
Besides changes in EQ-5D driven by the described events, the
decreases in EQ-5D utility index score were driven by time in the trial,
with a mean reduction during the 36 months of −0.03, and older age
(for example, at 36 months patients aged ≥75 years had a reduction
of −0.043 compared with −0.013 in patients aged <65 years; data
not shown).
After taking all the key factors and events into account (treat-
ment, sex, region, CV risk at baseline, stroke, cancer, severe hypogly-
caemia, confirmed hypoglycaemia, MI, HF, foot ulcer, retinopathy,
nephropathy, weight change of 5%, HbA1c < 58 mmol/mol, insulin
initiation and interaction between visit and age group at baseline), a
small treatment difference still appears to exist in the EQ-5D index
score (ETD 0.010, 95% CI 0.001-0.019; P = 0.0329), but not the VAS
(ETD 0.587, 95% CI −0.234-1.407; P = 0.1613), although it is possible
that this difference would disappear if every effect on treatment dif-
ference could be considered.
4 | DISCUSSION
LEADER is the first trial that we are aware of in patients with T2D at
high risk of CV disease to report a modest but significant benefit in
patient-reported health status using the EQ-5D with an antihypergly-
caemic agent (liraglutide) compared with placebo (both in addition to
standard of care). The data suggest that patients treated with liraglu-
tide experienced less deterioration of their HRQoL, gauged by both
utility index score and VAS score, over the trial duration. Because the
difference in favour of liraglutide was observed both with imputation
of values for death and without, the difference in HRQoL was not
solely explained by fewer deaths among liraglutide-treated patients.
Specifically, patients treated with liraglutide experienced a decelera-
tion in quality-of-life deterioration via the EQ-5D domains of self-care
and mobility, indicating that those taking liraglutide were better able
to retain abilities relating to washing, dressing and walking, compared
with those treated with placebo. Regarding categorical shifts (from no
problems at baseline to problems at 36 months, or problems at base-
line to no problems at 36 months), there was no significant difference
between treatment groups, as the majority of patients did not change
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FIGURE 1 A, Change in mean five-dimension European Quality of Life questionnaire (EQ-5D) index score. B, Change in mean EQ-5D visual
analogue scale (VAS) score. Estimated data. Patients with an observed value contributed to the analysis. Patients who died were given a value of
zero at the first planned visit after death. Change from baseline to 36-month assessment was analysed using a linear mixed model, accounting for
repeated measures within patients. Interaction between visit and treatment, sex, region and antidiabetic therapy, respectively, at baseline are
included as factors, and interaction between visit and baseline EQ-5D index/VAS score and age at baseline, respectively, are included as
covariates. EOT, end of trial
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categories during the trial. The binary categorization of “problems”
vs. “no problems” does not pick up the small changes in HRQoL, which
mainly seem to represent quantitative changes in the patients with
“problems”.
The ETD of 0.023 at 36 months (P = 0.020) observed in LEADER
should be considered important in comparison to published effects of
pharmacotherapy; for example, a study comparing an interventional
treatment strategy with a conservative treatment strategy in patients
with non-ST-segment elevation acute coronary syndrome found a sig-
nificant benefit from the interventional treatment compared with the
conservative treatment, with a mean treatment difference of 0.036
(P = 0.005) at 4 months, although this was no longer significant after
1 year (ETD 0.016; P = 0.20).13 In a cross-sectional survey of a ran-
dom sample of the English population including 26 104 subjects, pres-
ence of obesity (BMI ≥30 kg/m2) has been shown to lower mean EQ-
5D index score by −0.045 compared with absence of obesity
(P < 0.001), even when adjusted for confounding factors. More inter-
estingly, the presence of diabetes was shown to lower HRQoL mea-
sured by EQ-5D index score by −0.096, irrespective of sex, age group,
ethnicity, educational achievement or socio-economic position
(P < 0.001)14; therefore, the potential for liraglutide to slow this wors-
ening of HRQoL is relevant to this population.
The underlying causative factors for the difference in EQ-5D
score deterioration between treatment groups cannot be determined
with certainty, but could be attributable to the reduction in CV events
associated with liraglutide, other consequences of liraglutide treat-
ment not related to such events, or other events or factors displayed
in Figure 2. CV events have been found to play a key role in changes
in utility scores and HRQoL in ADVANCE,15 SAVOR-TIMI5 and the
UK Prospective Diabetes Study (UKPDS).16 In these studies, utility
scores for stroke (−0.199 to −0.099), MI (−0.051 to −0.026) and HF
(−0.134 to −0.045) were similar to those reported in the present
study (stroke −0.046, MI 0.004 and HF −0.055),5,15,16 although MI
did not appear to have an effect on the utility score in the present
study, possibly because the majority of MIs observed in LEADER were
non-ST-segment elevation events.17 We also found that hypoglycae-
mia and initiation of insulin were associated with reductions in
HRQoL, and may therefore play a role in the quality-of-life deteriora-
tion observed over the course of the trial as hypoglycaemia and new
insulin prescription occurred more frequently in placebo-treated
patients.6 The point estimate for effects of severe hypoglycaemia also
indicated an association with reduction in HRQoL, although this was
not statistically significant, possibly because of the low numbers of
patients with severe hypoglycaemic events.
TABLE 2 Categorical change in five-dimension European Quality of
Life questionnaire individual domain state scores from baseline to
36 months
EQ-5D domain Liraglutide N (%) Placebo N (%) P*
Mobility 0.036
Total 1223 (100.0) 1170 (100.0)
Worsening 188 (15.4) 188 (16.1)
No change 920 (75.2) 905 (77.4)
Improvement 115 (9.4) 77 (6.6)
Self-care 0.041
Total 1221 (100.0) 1169 (100.0)
Worsening 56 (4.6) 87 (7.4)
No change 1140 (93.4) 1048 (89.6)
Improvement 25 (2.0) 34 (2.9)
Usual activities 0.987
Total 1223 (100.0) 1169 (100.0)
Worsening 197 (16.1) 168 (14.4)
No change 916 (74.9) 896 (76.6)
Improvement 110 (9.0) 105 (9.0)
Pain/discomfort 0.081
Total 1223 (100.0) 1169 (100.0)
Worsening 256 (20.9) 249 (21.3)
No change 783 (64.0) 759 (64.9)
Improvement 184 (15.0) 161 (13.8)
Anxiety/depression 0.853
Total 1220 (100.0) 1169 (100.0)
Worsening 148 (12.1) 141 (12.1)
No change 946 (77.5) 915 (78.3)
Improvement 126 (10.3) 113 (9.7)
Abbreviations: EQ-5D, five-dimension European Quality of Life
questionnaire; N, number of patients contributing to the analysis.
Full analysis set. *P value from Kruskal–Wallis test of treatment difference
in all possible nine shifts ranked as: extreme problems to no problems;
some problems to no problems; no problems and no change; extreme
problems to some problems; some problems and no change; no problems
to some problems; extreme problems and no change; some problems to
extreme problems; no problems to extreme problems, by domain. No
adjustment for multiplicity has been made to P values.
TABLE 3 Categorical change in five-dimension European quality of life questionnaire utility index score at 36 months
Liraglutide Placebo
N (%) Mean (SD)a N (%) Mean (SD)a P*
Total 1256 (100.0) −0.05 (0.25) 1204 (100.0) −0.07 (0.26)
0.4156
Worsening 205 (16.3) −0.28 (0.19) 195 (16.2) −0.29 (0.20)
No change 919 (73.2) - 897 (74.5) -
No problems! still no problems 262 (20.9) 0.00 (0.00) 242 (20.1) 0.00 (0.00)
Problems! still problems 657 (52.3) −0.05 (0.28) 655 (54.4) −0.08 (0.28)
Improvement 132 (10.5) 0.23 (0.11) 112 (9.3) 0.25 (0.17)
Abbreviations: EQ-5D, five-dimension European Quality of Life questionnaire; SD, standard deviation. Full analysis set. No adjustment for multiplicity has
been made to the P value. A utility index score of 1 is classified as “no problems”, whereas scores <1 are classified as “problems”.
*P value from Kruskal–Wallis test of treatment difference in four-point shift, ranked in order of severity (worsening; problems to still problems; no prob-
lems to still no problems; improvement).
aMean (SD) change in EQ-5D utility index score within the category.
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The greatest reductions in HRQoL in the UKPDS were observed
in patients who experienced amputation, with an EQ-5D value of
−0.280.16 In the present study, wounds and amputations were cate-
gorized as “foot ulcers” with no detailed differentiation, and relatively
few patients experienced these (n = 113/3014). This may explain why
there is only a relatively small decrease in the EQ-5D utility index
score of −0.023 (P = 0.060) after patients have a foot ulcer (including
wounds and amputations) in LEADER, and a similarly small decrease
was observed in the VAS (−1.881, P = 0.058; Figure 2).
The decreases in EQ-5D utility index scores of −0.058 with lira-
glutide and − 0.082 with placebo at 36 months in LEADER are consis-
tent with other datasets; for comparison, the ADVANCE trial in
patients with T2D showed a reduction in EQ-5D utility score of
−0.030 independent of complications over 5 years.15 It should be
noted that there were differences between patient populations in the
ADVANCE and LEADER trials,6,15 and so quantitative comparisons
between the reductions in HRQoL are difficult to assess. However, it
is clear that, as T2D is a progressive disease, some reduction in
HRQoL can be expected over long time periods as a result of the com-
plications associated with aging and diabetes.18
Currently, no other trials that we are aware of in patients with
T2D at high risk of CV disease have reported significantly less deterio-
ration in HRQoL with a pharmacological intervention compared with
placebo; therefore, the demonstration of the ability of liraglutide to
slow this decline is noteworthy. The SAVOR-TIMI-53 trial of saxaglip-
tin, the only other CV outcomes trial (CVOT) in diabetes to report
HRQoL outcomes, reported no CV benefit compared with placebo,
and no significant differences in HRQoL between treatment groups.5
The EMPA-REG, CANVAS, EXSCEL and SUSTAIN-6 studies, which
are the other published CVOTs of diabetes therapies to report a CV
Effect
Subjects/measurements
(no vs. yes)
Estimated difference
Estimate [95% CI] P-value
Stroke 2907/13503 vs. 89/207 –0.046 0.0014
MI 2829/13270 vs. 167/440 0.004 0.6960
Heart failure 2883/13439 vs. 113/271 –0.055 <0.0001
Malignant neoplasm 2809/13227 vs. 187/483 –0.029 0.0029
Severe hypoglycaemic
episode 2927/13538 vs. 69/172 –0.029 0.0728
Confirmed hypoglycaemic
episode 1730/9442 vs. 1266/4268
–0.018 0.0001
Foot ulcer 2883/13427 vs. 113/283 –0.023 0.0600
Retinopathy 2934/13523 vs. 62/187 –0.001 0.9662
Nephropathy 2837/13269 vs. 159/441 –0.004 0.6971
Insulin initiation 2406/11947 vs. 590/1763 –0.010 0.0655
Weight loss of 5% from
baseline 1695/9677 vs. 1301/4033 0.008 0.0780
HbA1c <58 mmol/mol 553/4134 vs. 2443/9576 0.011
[–0.074;–0.019]
[–0.016;0.024]
[–0.080;–0.030]
[–0.048;–0.010]
[–0.061;0.003]
[–0.027;–0.010]
[–0.048;0.001]
[–0.032;0.031]
[–0.024;0.016]
[–0.021;0.001]
[–0.001;0.016]
[0.002;0.019] 0.0198
0 0.02–0.02 0.04–0.04–0.06–0.08
(A)
Effect
Subjects/measurements
(no vs. yes)
Estimated difference
Estimate [95% CI] P-value
Stroke 2872/13306 vs. 88/204 –5.771 <0.0001
MI 2795/13076 vs. 165/434 –0.756 0.3512
Heart failure 2848/13244 vs. 112/266 –1.132 0.2635
Malignant neoplasm 2775/13037 vs. 185/473 –2.838 0.0003
Severe hypoglycaemic
episode 2892/13340 vs. 68/170 –1.416 0.2684
Confirmed hypoglycaemic
episode 1708/9310 vs. 1252/4200
–0.009 0.9784
Foot ulcer 2848/13231 vs. 112/279 –1.881 0.0582
Retinopathy 2898/13324 vs. 62/186 0.297 0.8146
Nephropathy 2804/13079 vs. 156/431 –0.530 0.5109
Insulin initiation 2377/11772 vs. 583/1738 –1.020 0.0230
Weight loss of 5% from
baseline 1679/9553 vs. 1281/3957 0.235 0.5009
HbA1c <58 mmol/mol 542/4067 vs. 2418/9443 0.192
[–7.992;–3.550]
[–2.353;0.841]
[–3.128;0.864]
[–4.347;–1.330]
[–3.948;1.116]
[–0.697;0.678]
[–3.828;0.067]
[–2.223;2.816]
[–2.117;1.058]
[–1.899;–0.141]
[–0.449;0.918]
[–0.522;0.905] 0.5987
0 2–2 4–4–6–8
(B)
FIGURE 2 A, Change in five-dimension European Quality of Life questionnaire (EQ-5D) utility index score for key factors and events. B, Change
in EQ-5D visual analogue scale (VAS) score for key factors and events. Change from baseline analysed using a linear mixed model accounting for
repeated measures within patients using a compound symmetry residual covariance matrix. Factors: treatment, sex, region, cardiovascular
(CV) risk at baseline, stroke, cancer, severe hypoglycaemia, confirmed hypoglycaemia, myocardial infarction (MI), heart failure, foot ulcer,
retinopathy, nephropathy, weight change of 5%, glycated haemoglobin (HbA1c) <58 mmol/mol, insulin initiation and interaction between visit
and age group at baseline. Baseline value of analysed parameter is included as covariate. The factors of the events are given a value of “no” at
time points before the given event, and a value of “yes” at time points after a given event. Patients from the following countries are included:
Canada, Denmark, Ireland, Italy, Netherlands, Germany, Spain, Sweden, United Kingdom and United States
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benefit with active treatment vs. placebo, have not yet reported
results from HRQoL measures such as the EQ-5D.19–21 A recent
review article highlighted that EQ-5D utility index score showed no
significant change from baseline in trials with numerous antihypergly-
caemic therapies, including exenatide (twice daily and once weekly),
dulaglutide, liraglutide, dapagliflozin and insulin glargine.22
The only other study of liraglutide in which EQ-5D data were col-
lected looked at patient preferences for liraglutide compared with
exenatide (twice daily). In this study, while patients indicated a prefer-
ence for liraglutide based on superior efficacy and lower degree of
nausea and hypoglycaemia, there was no assessment for treatment
effect.23 Results from the current analysis show that liraglutide is
associated with a slower decline in HRQoL, presently a novel finding.
The strengths of this secondary analysis include the double-
blinded nature of the LEADER trial, inclusion of a large subset of the
total cohort and comprehensive collection of EQ-5D data at multiple
time points. The results show a high degree of consistency between
EQ-5D utility index scores and VAS assessments.
There are, however, some factors that may limit the interpretation
of this analysis. First, EQ-5D measurements were taken 12 months
apart, so transient HRQoL changes (with a duration of <1 year) that
were influenced by an event may not be captured. This analysis was
not designed to investigate changes in EQ-5D following an event, and
to do so would require patients answering the EQ-5D questionnaire
before and after an event, instead of at specified time points. The
analysis only included Western countries, as the EQ-5D is only avail-
able in the language of those countries; this may have caused a
patient selection bias. It is not clear whether this bias may have had
an impact on the results; however, patients in the countries in this
sub-study experienced a similar reduced risk of CV outcomes com-
pared with those in the overall trial, probably diminishing a
selection bias.
Although the EQ-5D can be sensitive to the onset of diabetes
complications, such as stroke, ischaemic heart disease and
neuropathy,24,25 the scale has been criticised for being insensitive to
small changes in health status in T2D.26 The EQ-5D is considered by
some to be less responsive or sensitive than disease-specific outcome
measures. However, since there is no “gold standard” for patient-
reported outcomes, questions remain as to which measure is defini-
tively the most appropriate for this population,22 and psychometric
evidence alongside these patient-reported outcomes may be required
to validate and interpret the impact of the measures. Finally, the
LEADER trial did not pre-specify any expected benefit in EQ-5D score
compared with placebo as part of a hypothesis, and the findings might
be considered relevant only to those with T2D and high CV risk.
In conclusion, the results of this exploratory analysis show that
the established positive safety and efficacy results observed in the
LEADER trial may have a positive impact on quality of life (reported
here over a period of 36 months), and this requires further confirma-
tory research.
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